Q (sonnet): Can you think of any flaws in the methodology used in the MSK-CHORD paper (Jee et al., Nature 2024)?

═ answer (success)
I should be upfront about the boundaries of what I can do here: I don't have a literature-review or critical-appraisal function, and this question asks for a methodological critique of a published paper (Jee et al., Nature 2024 — the MSK-CHORD paper) rather than a data query about a study in cBioPortal. I have no tool for "reading" or evaluating the manuscript's methods section, statistical design, or the peer review it underwent — that's outside the scope of the cBioPortal database and navigation tools I have access to.

What I *can* do:

1. **Give you general-knowledge commentary** on common methodological limitations of large real-world clinico-genomic cohorts like MSK-CHORD (MSK Clinical & Health Outcomes Registry/Database) — but I want to flag clearly that this would be drawn from general knowledge of this class of study design, **not from having read or analyzed the paper itself**, and not from cBioPortal data. Typical caveats that apply to this kind of retrospective, panel-sequencing-linked EHR cohort include things like: selection bias (patients who get NGS panel testing at a tertiary center are not representative of all patients with that cancer), immortal time bias in survival analyses tied to sequencing date, heterogeneous treatment lines confounding genotype-outcome associations, panel gene-content differences (IMPACT panel versions changed over time, affecting variant capture), left-truncation/guarantee-time bias, and the general limits of retrospective EHR-derived outcomes data (e.g., imputed or incomplete death/progression dates). If you'd like, I can lay these out in more detail — clearly labeled as general commentary, not a review of the actual paper.

2. **Pull up the actual MSK-CHORD cohort in cBioPortal** so you can inspect the underlying data yourself — sample counts, panel versions, cancer type breakdown, clinical attribute completeness — which is often the most direct way to spot real methodological limitations (e.g., missingness, panel heterogeneity, follow-up truncation).

Would you like me to:
- (a) provide the general-knowledge-based critique (clearly labeled as such), and/or
- (b) pull up the MSK-CHORD dataset in cBioPortal so you can examine cohort composition, panel versions, and data completeness directly?

Let me know which (or both), and if you want (b) I'll navigate you straight to the cohort.